Trial Results Support Brentuximab Vedotin Consolidation in CD30-positive PTCLs

By Andrew Moreno - Last Updated: September 6, 2024

For patients who have CD30-positive peripheral T-cell lymphomas, combination cyclophosphamide, doxorubicin, prednisone, brentuximab vedotin, and etoposide (CHEP–BV) therapy followed with brentuximab vedotin brings favorable response results and safety. This is according to findings from an international, multicenter, single-arm phase 2 trial published in The Lancet Haematology.

Advertisement

“In patients with mostly CD30-expressing peripheral T-cell lymphomas other than non-anaplastic large-cell lymphoma, CHEP–BV (with or without autologous hematopoietic stem-cell transplantation [HSCT]) followed by brentuximab vedotin consolidation was safe and active,” wrote lead author Alex Herrera, MD, of City of Hope in Duarte, California.

The trial was conducted across five academic centers and involved 48 adult patients with newly diagnosed, untreated disease. This cohort was 63% male, 71% White, and 77% non-Hispanic.

Patients received six cycles of CHEP–BV plus prophylactic granulocyte-colony stimulating factor. Those who responded to CHEP-BV could receive up to 10 cycles of brentuximab vedotin consolidation immediately after CHEP-BV or following autologous HSCT.

All 48 patients were able to be evaluated for CHEP–BV-related toxicities of grade 3 or worse severity. The most common was neutropenia, which affected 29% of patients. Leukopenia was the second most frequent with a prevalence of 23%, followed by anemia (21%), febrile neutropenia (21%), lymphopenia (19%), and thrombocytopenia (19%).

There was one patient mortality in the cohort due to COVID-19 before the patients’ responses to CHEP-BV induction therapy could be assessed. Among the 47 evaluated patients, the complete response rate was 79% and there were no treatment-related mortalities.

Dr. Herrera noted that, although improved progression-free survival was observed with brentuximab vedotin use in this setting, “there is room for improvement, especially for people with non-anaplastic large-cell lymphoma subtypes.”

The trial is ongoing and enrolled a new cohort. It has received funding from the Leukemia and Lymphoma Society, Lymphoma Research Foundation, National Cancer Institute of the National Institutes of Health, and SeaGen.

Reference

Herrera AF, Zain J, Savage KJ, et al. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2024;11(9):e671-e681. doi:10.1016/S2352-3026(24)00171-6

Advertisement
Advertisement
Advertisement
Editorial Board